Brian P. Kearney

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax, Edwin DeJesus, Anthony Mills et al. · The Lancet · 2012 · 444 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus, Jürgen K. Rockstroh, Keith Henry et al. · The Lancet · 2012 · 346 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

Patricia Barditch‐Crovo, Steven G. Deeks, Ann Collier et al. · Antimicrobial Agents and Chemotherapy · 2001 · 333 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

Edwin DeJesus, Daniel Berger, Martin Markowitz et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2006 · 269 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity

Anita Mathias, Polina German, Bernard P. Murray et al. · Clinical Pharmacology & Therapeutics · 2009 · 208 citations

Medicine, Pharmacokinetics, Pharmacology +15